Document:

Form of Warrant

 EXHIBIT 4.3 
  

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAW. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT AND APPLICABLE STATE SECURITIES
LAWS, SUPPORTED BY AN OPINION OF COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
  
 POINT THERAPEUTICS, INC. 
  
 Warrant for the Purchase of Shares of 
 Common Stock

  

			
	 No. PW-«number»
	 	«shares» Shares

  
 FOR VALUE RECEIVED,
POINT THERAPEUTICS, INC., a Delaware corporation (the “Company”), hereby certifies that «name», its designee or its permitted assigns is entitled to purchase from the Company, at any time or from time to time commencing
on September 27, 2004 and prior to 5:00 P.M., New York City time, on September 27, 2009, «sharesout» fully paid and non-assessable shares of common stock, $.01 par value per share, of the Company for an aggregate purchase price of
«amount». (Hereinafter, (i) said common stock, $.01 par value per share, of the Company, is referred to as the “Common Stock”; (ii) the shares of the Common Stock (subject to adjustment) purchasable hereunder or under
any other Warrant (as hereinafter defined) are referred to as the “Warrant Shares”; (iii) the aggregate purchase price payable for the Warrant Shares purchasable hereunder is referred to as the “Aggregate Warrant
Price”; (iv) the price payable (initially $6.25 per share subject to adjustment) for each of the Warrant Shares hereunder is referred to as the “Per Share Warrant Price”; (v) this Warrant, all similar Warrants issued on the
date hereof and all warrants hereafter issued in exchange or substitution for this Warrant or such similar Warrants are referred to as the “Warrants”; (vi) the holder of this Warrant is referred to as the “Holder”
and the holder of this Warrant and all other Warrants and Warrant Shares are referred to as the “Holders” and Holders of more than fifty percent (50%) of the outstanding Warrant Shares are referred to as the “Majority of the
Holders”); and (vii) the then Current Market Price per share of the Common Stock (the “Current Market Price”) shall be deemed to be the last reported sale price of the Common Stock on the Trading Day immediately prior to
such date or, in case no such reported sales take place on such day, the average of the last reported bid and asked prices of the Common Stock on such day, in either case on the principal national securities exchange on which the Common Stock is
admitted to trading or listed, or if not listed or admitted to trading on any such exchange, the representative closing sale price of the Common Stock as reported by the National Association of Securities Dealers, Inc. Automated Quotations System
(“NASDAQ”), or other similar organization if NASDAQ is no longer reporting such information, or, if the Common Stock is not reported on NASDAQ, the per share sale price for the Common Stock in the over-the-counter market as reported
by the National Quotation Bureau or similar organization, or if not so available, the fair market value of the Common Stock as 

 determined in good faith by the Board of Directors. A “Trading Day” shall mean any day on which shares
of the Company’s Common Stock are sold on the respective exchange. The Aggregate Warrant Price is not subject to adjustment. The Per Share Warrant Price is subject to adjustment as hereinafter provided; in the event of any such adjustment, the
number of Warrant Shares deliverable upon exercise of this Warrant shall be adjusted by dividing the Aggregate Warrant Price by the Per Share Warrant Price in effect immediately after such adjustment. 
  
 This Warrant, together with warrants of like tenor, constituting in the
aggregate Warrants to purchase 900,000 Warrant Shares, was originally issued pursuant to a Securities Purchase Agreement (the “Securities Purchase Agreement”) between the Company and the investor named therein in connection with a
private placement by the Company of its securities. By acceptance of this Warrant, the Holder agrees to comply with all applicable provisions of the Securities Purchase Agreement. 
  

	1.	Exercise of Warrant. 

  
 (a) This Warrant may be exercised in whole at any time, or in part from time to time, commencing on September 27, 2004 and prior to 5:00 P.M., New York
City time, on September 27, 2009 by the Holder: 
  
 (i) by the surrender of this Warrant (with the subscription form at the end hereof duly executed) at the address set forth in Section 9(a) hereof, together with proper payment of the Aggregate Warrant Price, or the proportionate part
thereof if this Warrant is exercised in part, with payment for the Warrant Shares made by certified or official bank check payable to the order of the Company; or 
  
 (ii) by the surrender of this Warrant (with the cashless exercise form at the end hereof duly executed) (a
“Cashless Exercise”) at the address set forth in Section 9(a) hereof; provided, however, that such Cashless Exercise shall be available to the Holder only and for so long as a Registration Statement fails to be effective and
available to the Holder as to the Warrant Shares. Such presentation and surrender shall be deemed a waiver of the Holder’s obligation to pay the Aggregate Warrant Price, or the proportionate part thereof if this Warrant is exercised in part. In
the event of a Cashless Exercise, the Holder shall exchange its Warrant for that number of Warrant Shares subject to such Cashless Exercise multiplied by a fraction, the numerator of which shall be the difference between the then Current Market
Price and the Per Share Warrant Price, and the denominator of which shall be the then Current Market Price. For purposes of any computation under this Section 1(a), the then Current Market Price shall be based on the Trading Day immediately
preceding such Cashless Exercise. 
  
 (b) If this Warrant is
exercised in part, this Warrant must be exercised for a number of whole shares of the Common Stock and the Holder is entitled to receive a new Warrant covering the Warrant Shares that have not been exercised and setting forth the proportionate part
of the Aggregate Warrant Price applicable to such Warrant Shares. Upon surrender of this Warrant, the Company will, within three (3) Trading Days, (i) issue a certificate or certificates in the name of the Holder for the largest number of whole
shares of the Common Stock to which the Holder shall be entitled and, if this Warrant is exercised in whole, in lieu of any fractional share of the Common Stock to which the Holder shall be entitled, pay to the Holder cash in an amount equal to the
fair value of such fractional share (determined in such reasonable manner as the Board of Directors of the Company shall determine), and (ii) deliver the other securities and properties receivable upon the exercise of this Warrant, or the
proportionate part thereof, if this Warrant is exercised in part, pursuant to the provisions of this Warrant. 
  

 2 

	 	2.	Reservation of Warrant Shares; Listing. 

  
 The Company agrees that, prior to the expiration of this Warrant, the Company shall at all times (a) have authorized and in reserve, and shall keep
available, solely for issuance and delivery upon the exercise of this Warrant, the shares of the Common Stock and other securities and properties as from time to time shall be receivable upon the exercise of this Warrant, free and clear of all
restrictions on sale or transfer, other than under Federal or state securities laws, and free and clear of all preemptive rights and rights of first refusal and (b) if the Company hereafter lists its Common Stock on any national securities exchange,
the Nasdaq National Market or the Nasdaq Smallcap Market, use its best efforts to keep the Warrant Shares authorized for listing on such exchange upon notice of issuance. 
  

	 	3.	Protection Against Dilution. 

  
 (a) If, at any time or from time to time after the date of this Warrant, the Company shall issue or distribute to the holders of shares of Common Stock
evidence of its indebtedness, any other securities of the Company or any cash, property or other assets (excluding a subdivision, combination or reclassification, or dividend or distribution payable in shares of Common Stock, referred to in Section
3(b), and also excluding cash dividends or cash distributions paid out of net profits legally available therefor (any such non-excluded event being herein called a “Special Dividend”)), the Per Share Warrant Price shall be adjusted
by multiplying the Per Share Warrant Price then in effect by a fraction, the numerator of which shall be the then Current Market Price in effect on the record date of such issuance or distribution less the fair market value (as determined in good
faith by the Company’s Board of Directors) of the evidence of indebtedness, cash, securities or property, or other assets issued or distributed in such Special Dividend applicable to one share of Common Stock and the denominator of which shall
be the then Current Market Price in effect on the record date of such issuance or distribution. An adjustment made pursuant to this Subsection 3(a) shall become effective immediately after the record date of any such Special Dividend and shall
result in a corresponding adjustment to the number of Warrant Shares issuable upon exercise of this Warrant. 
  
 (b) In case the Company shall hereafter (i) pay a dividend or make a distribution on its capital stock in shares of Common Stock, (ii) subdivide its
outstanding shares of Common Stock into a greater number of shares, (iii) combine its outstanding shares of Common Stock into a smaller number of shares or (iv) issue by reclassification of its Common Stock any shares of capital stock of the
Company, the Per Share Warrant Price shall be adjusted to be equal to a fraction, the numerator of which shall be the Aggregate Warrant Price and the denominator of which shall be the number of shares of Common Stock or other capital stock of the
Company that the Holder would have owned immediately following such action had such Warrant been exercised immediately prior thereto. An adjustment made pursuant to this Subsection 3(b) shall become effective immediately after the record date in the
case of a dividend or distribution, and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification, and shall result in a corresponding adjustment to the number of Warrant Shares
issuable upon exercise of this Warrant. 
  
 (c) Except as provided
in Subsections 3(a) and 3(d), in case the Company shall hereafter issue or sell any Common Stock, any securities convertible into Common Stock, any rights, options or warrants to purchase or otherwise receive issuances of Common Stock or any
securities convertible into, or exercisable or exchangeable for, Common Stock, in each case 
  

 3 

 for a price per share or entitling the holders thereof to purchase Common Stock at a price per share (determined by
dividing (i) the total amount, if any, received or receivable by the Company in consideration of the issuance or sale of such securities plus the total consideration, if any, payable to the Company upon exercise thereof (the “Total
Consideration”) by (ii) the number of additional shares of Common Stock issued, sold or issueable upon exercise of such securities) that is less than the Per Share Warrant Price in effect on the date of such issuance or sale, then the Per
Share Warrant Price shall be adjusted as of the date of such issuance or sale by multiplying the Per Share Warrant Price then in effect by a fraction, the numerator of which shall be (x) the sum of (A) the number of shares of Common Stock
outstanding on the record date of such issuance or sale (calculated on a fully diluted basis as if all securities exercisable, convertible or exchangeable for Common Stock have been so exercised, converted or exchanged) plus (B) the Total
Consideration divided by the current Per Share Warrant Price, and the denominator of which shall be (y) the number of shares of Common Stock outstanding on the record date of such issuance or sale (calculated on a fully diluted basis as if all
securities exercisable, convertible or exchangeable for Common Stock have been so exercised, converted or exchanged) plus the maximum number of additional shares of Common Stock issued, sold or issueable upon exercise or conversion of such
securities. Notwithstanding anything herein to the contrary, in no event shall the Per Share Warrant Price be adjusted below $[market price on day of Closing]. An adjustment to the Per Share Warrant Price made pursuant to this Subsection 3(c) shall
result in a corresponding adjustment to the number of Warrant Shares issuable upon exercise of this Warrant. 
  
 (d) No adjustment in the Per Share Warrant Price shall be required in the case of the issuance by the Company of Common Stock or other convertible
securities (i) pursuant to any stock options, warrants or other convertible securities currently outstanding; (ii) stock options, warrants or other convertible securities issued after the date hereof, which may be approved by the Company’s
Board of Directors pursuant to any Company benefit plan or exercised under any employee benefit plan of the Company to officers, directors, consultants or employees, but only with respect to such warrants or stock options as are exercisable at
prices no lower than the closing price of the Common Stock as of the date of grant thereof; or (iii) upon the issuance of Common Stock pursuant to the Warrants or the Subscription Agreement or any warrants outstanding as of the date hereof,
including, without limitation, the warrants issued to investors of the Company pursuant to the private placement that closed in September of 2003. 
  
 (e) In case of any capital reorganization or reclassification, or any consolidation or merger to which the Company is a party other than a merger or
consolidation in which the Company is the continuing corporation, or in case of any sale or conveyance to another entity of the property of the Company as an entirety or substantially as an entirety, or in the case of any statutory exchange of
securities with another corporation (including any exchange effected in connection with a merger of a third corporation into the Company), the Holder of this Warrant shall have the right thereafter to receive on the exercise of this Warrant the kind
and amount of securities, cash or other property which the Holder would have owned or have been entitled to receive immediately after such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance had this
Warrant been exercised immediately prior to the effective date of such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance and in any such case, if necessary, appropriate adjustment shall be made in the
application of the provisions set forth in this Section 3 with respect to the rights and interests thereafter of the Holder of this Warrant to the end that the provisions set forth in this Section 3 shall thereafter correspondingly be made
applicable, as nearly as may reasonably be, in relation to any shares of stock or other securities or property thereafter deliverable on the exercise of this Warrant. The above provisions of this Section 3(c) shall similarly apply to successive
reorganizations, reclassifications, consolidations, mergers, statutory exchanges, sales or conveyances. The Company shall require the issuer of any shares 
  

 4 

 of stock or other securities or property thereafter deliverable on the exercise of this Warrant to be responsible for all
of the agreements and obligations of the Company hereunder. Notice of any such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance and of said provisions so proposed to be made, shall be mailed to the
Holders of the Warrants not less than thirty (30) days prior to such event. A sale of all or substantially all of the assets of the Company for a consideration consisting primarily of securities shall be deemed a consolidation or merger for the
foregoing purposes. 
  
 (f) No adjustment in the Per Share Warrant
Price shall be required unless such adjustment would require an increase or decrease of at least $0.01 per share of Common Stock; provided, however, that any adjustments which by reason of this Subsection 3(f) are not required to be
made shall be carried forward and taken into account in any subsequent adjustment; provided, further, however, that adjustments shall be required and made in accordance with the provisions of this Section 3 (other than this Subsection
3(f)) not later than such time as may be required in order to preserve the tax-free nature of a distribution to the Holder of this Warrant or Common Stock issuable upon the exercise hereof. All calculations under this Section 3 shall be made to the
nearest cent or to the nearest 1/100th of a share, as the case may be. 
  
 (g) Whenever the Per Share Warrant Price is adjusted as provided in this Section 3 and upon any modification of the rights of a Holder of Warrants in accordance with this Section 3, the Company shall promptly prepare a brief statement of
the facts requiring such adjustment or modification and the manner of computing the same and cause copies of such certificate to be mailed to the Holders of the Warrants. 
  
 (h) If the Board of Directors of the Company shall declare any dividend or other distribution with respect to the Common
Stock other than a cash distribution out of earned surplus, the Company shall mail notice thereof to the Holders of the Warrants not less than ten (10) days prior to the record date fixed for determining stockholders entitled to participate in such
dividend or other distribution. 
  
 (i) If, as a result of an
adjustment made pursuant to this Section 3, the Holder of any Warrant thereafter surrendered for exercise shall become entitled to receive shares of two or more classes of capital stock or shares of Common Stock and other capital stock of the
Company, the Board of Directors (whose determination shall be conclusive and shall be described in a written notice to the Holder of any Warrant promptly after such adjustment) shall determine the allocation of the adjusted Per Share Warrant Price
between or among shares or such classes of capital stock or shares of Common Stock and other capital stock. 
  
 (j) In case any event shall occur as to which the other provisions of this Section 3 are not strictly applicable but as to which the failure to make any
adjustment would not fairly protect the purchase rights represented by this Warrant in accordance with the essential intent and principles hereof then, in each such case, the Board of Directors of the Company shall in good faith determine the
adjustment, if any, on a basis consistent with the essential intent and principles established herein, necessary to preserve the purchase rights represented by the Warrants. Upon such determination, the Company will promptly mail a copy thereof to
the Holder of this Warrant and shall make the adjustments described therein. 
  
 4. Fully Paid Stock; Taxes. The shares of the Common Stock represented by each and every certificate for Warrant Shares delivered on the exercise of this Warrant shall at the time of such delivery, be
duly authorized, validly issued and outstanding, fully paid and nonassessable, and not subject to preemptive rights or rights of first refusal, and the Company 
  

 5 

 will take all such actions as may be necessary to assure that the par value, if any, per share of the Common Stock is at
all times equal to or less than the then Per Share Warrant Price. The Company shall pay, when due and payable, any and all Federal and state stamp, original issue or similar taxes which may be payable in respect of the issue of any Warrant Share or
any certificate thereof to the extent required because of the issuance by the Company of such security. 
  

	 	5.	Registration Under Securities Act of 1933. 

  
 (a) The Holder shall have the right to participate in the registration rights granted to purchasers of the Common Stock pursuant to the Registration
Rights Agreement between such purchasers and the Company that were entered into at the time of the initial sale of the Common Stock. By acceptance of this Warrant, the Holder agrees to comply with the provisions of the Registration Rights Agreement
to same extent as if it were a party thereto. 
  
 (b) Until all of
the Warrant Shares have been sold under a Registration Statement or pursuant to Rule 144(k), so long as the Company’s Common Stock remains registered under the Securities Act of 1934, as amended, the Company shall use its reasonable best
efforts to file with the Securities and Exchange Commission all current reports and the information as may be necessary to enable the Holder to effect sales of its shares in reliance upon Rule 144(k) promulgated under the Act. 
  

	 	6.	Investment Intent; Limited Transferability. 

  
 (a) By accepting this Warrant the Holder represents that it understands that this Warrant and any securities obtainable upon exercise of this Warrant have
not been registered for sale under Federal or state securities laws and are being offered and sold to the Holder pursuant to one or more exemptions from the registration requirements of such securities laws. In the absence of an effective
registration of such securities or an exemption therefrom, any certificates for such securities shall bear the legend set forth on the first page hereof. The Holder understands that it must bear the economic risk of its investment in this Warrant
and any securities obtainable upon exercise of this Warrant for an indefinite period of time, as this Warrant and such securities have not been registered under Federal or state securities laws and therefore cannot be sold unless subsequently
registered under such laws, unless an exemption from such registration is available. 
  
 (b) The Holder, by its acceptance of this Warrant, represents to the Company that it is acquiring this Warrant and will acquire any securities obtainable upon exercise of this Warrant for its own account for
investment and not with a view to, or for sale in connection with, any distribution thereof in violation of the Securities Act of 1933, as amended (the “Act”). The Holder agrees that this Warrant and any such securities will not be sold or
otherwise transferred unless (i) a registration statement with respect to such transfer is effective under the Act and any applicable state securities laws or (ii) such sale or transfer is made pursuant to one or more exemptions from the Act as
supported by an opinion of counsel to the Holder. 
  
 (c) In
addition to the limitations set forth in Section 1, this Warrant may not be sold, transferred, assigned or hypothecated by the Holder except in compliance with the provisions of the Act and the applicable state securities “blue sky” laws,
and is so transferable only upon the books of the Company which it shall cause to be maintained for such purpose. The Company may treat the registered Holder of this Warrant as it appears on the Company’s books at any time as the Holder for all
purposes. The Company shall permit any Holder of a Warrant or its duly authorized attorney, upon written request during ordinary business hours, to inspect and copy or make extracts from its books showing the registered Holders of Warrant. All
Warrants issued upon the transfer or assignment of this Warrant will be dated the same date as this Warrant, and all rights of the holder thereof shall be identical to those of the Holder. 
  

 6 

 7. Loss, etc., of Warrant. Upon receipt of evidence satisfactory to the Company of the
loss, theft, destruction or mutilation of this Warrant, and of indemnity reasonably satisfactory to the Company, if lost, stolen or destroyed, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver
to the Holder a new Warrant of like date, tenor and denomination. 
  
 8. Warrant Holder Not Stockholder. This Warrant does not confer upon the Holder any right to vote on or consent to or receive notice as a stockholder of the Company, as such, in respect of any matters whatsoever, nor any other
rights or liabilities as a stockholder, prior to the exercise hereof; this Warrant does, however, require certain notices to Holders as set forth herein. 
  
 9. Communication. No notice or other communication under this Warrant shall be effective unless, however, any notice or other communication
shall be effective and shall be deemed to have been given if, the same is in writing and is mailed by first-class mail, postage prepaid, addressed to: 
  
 (a) the Company at Point Therapeutics, Inc., 125 Summer St., Boston, MA 02110 Facsimile: (617) 933-2130, Attn: President, or such other
address as the Company has designated in writing to the Holder, or 
  
 (b) the Holder at «address» or other such address as the Holder has designated in writing to the Company. 
  
 10. Headings. The headings of this Warrant have been inserted as a matter of convenience and shall not affect the construction hereof.

  
 11. Applicable Law. This Warrant shall be
governed by and construed in accordance with the law of the State of New York without giving effect to the principles of conflicts of law thereof. 
  
 12. Amendment, Waiver, etc. Except as expressly provided herein, neither this Warrant nor any term hereof may be amended, waived, discharged
or terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought; provided, however, that any provisions hereof may be amended, waived, discharged or
terminated upon the written consent of the Company and the Majority of the Holders. 
  

 7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by its President and has caused its
corporate seal to be hereunto affixed and attested by its Secretary this 26th day of March, 2004. 
  

			
	POINT THERAPEUTICS, INC.
		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

  

	
	 ATTEST:

	
	  

	 Secretary

	
	 [Corporate Seal]

  

 8 

 SUBSCRIPTION (cash) 
  
 The undersigned,
                            , pursuant to the provisions of the foregoing Warrant, hereby agrees to
subscribe for and purchase                                  shares of the Common
Stock, par value $.01 per share, of Point Therapeutics, Inc. covered by said Warrant, and makes payment therefor in full at the price per share provided by said Warrant. 
  

							
	 Dated:
	 	  

	 	 	 	 
	 	 	 	 	Signature:	 	  

				
	 	 	 	 	Address:	 	  

  

  
 CASHLESS EXERCISE 
  
 The undersigned                     , pursuant
to the provisions of the foregoing Warrant, hereby elects to exchange its Warrant for
                                 shares of Common Stock, par value $.01 per share,
of Point Therapeutics, Inc. pursuant to the Cashless Exercise provisions of the Warrant. 
  

							
	 Dated:
	 	  

	 	 	 	 
	 	 	 	 	Signature:	 	  

				
	 	 	 	 	Address:	 	  

  

 9 

 ASSIGNMENT 
  
 FOR VALUE RECEIVED
                         hereby sells, assigns and transfers unto
                                 the foregoing Warrant and all rights evidenced
thereby, and does irrevocably constitute and appoint                             , attorney, to
transfer said Warrant on the books of Point Therapeutics, Inc. 
  

							
	 Dated:
	 	  

	 	 	 	 
	 	 	 	 	Signature:	 	  

				
	 	 	 	 	Address:	 	  

  
 PARTIAL
ASSIGNMENT 
  
 FOR VALUE RECEIVED
                         hereby assigns and transfers unto
                             the right to purchase
             shares of Common Stock, par value $.01 per share, of Point Therapeutics, Inc. covered by the foregoing Warrant, and a proportionate part of said Warrant and the rights
evidenced thereby, and does irrevocably constitute and appoint                             , attorney,
to transfer such part of said Warrant on the books of Point Therapeutics, Inc. 
  

							
	 Dated:
	 	  

	 	 	 	 
	 	 	 	 	Signature:	 	  

				
	 	 	 	 	Address:	 	  

  

 10Securities Purchase Agreement dated as of March 31,2004

 Exhibit 10.1 
  
 SECURITIES PURCHASE AGREEMENT 
  

SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 31, 2004, by and among Internet Capital Group, Inc., a
Delaware corporation with headquarters located at 690 Lee Road, Suite 310, Wayne, Pennsylvania 19087 (the “Company”), and the investors listed on the Schedule of Buyers attached as Schedule I hereto (individually, a
“Buyer” and collectively, the “Buyers”). 
  
 WHEREAS: 
  
 A. The Company and each Buyer
are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506 of Regulation D
(“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the 1933 Act. 
  
 B. The Company has authorized a new series of senior convertible notes of the Company in the form attached hereto as Exhibit A (together with any senior
convertible notes issued in replacement thereof in accordance with the terms thereof, the “Notes”), which Notes shall be convertible into shares of the Company’s common stock, par value $0.001 per share (the “Common
Stock”) (as converted, the “Conversion Shares”), in accordance with the terms and conditions of the Notes. 
  
 C. The Notes bear interest, which at the option of the Company, subject to certain conditions, may be paid in shares of Common Stock (the “Interest
Shares”). 
  
 D. Each Buyer wishes to purchase, severally but not
jointly, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) that aggregate principal amount of Notes set forth opposite such Buyer’s name on the Schedule of Buyers under the heading “Principal
Amount” (which aggregate principal amount for all Buyers shall be $60,000,000) 
  
 E. Contemporaneously with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement, substantially in the form attached hereto as Exhibit B (the
“Registration Rights Agreement”), pursuant to which the Company has agreed to provide certain registration rights with respect to the Notes, the Conversion Shares and the Interest Shares under the 1933 Act and the rules and
regulations promulgated thereunder, and applicable state securities laws. 
  
 F.
The Notes, the Conversion Shares and the Interest Shares collectively are referred to herein as the “Securities”. 
  

 NOW, THEREFORE, the Company and each Buyer (with respect only to itself) hereby agree as follows: 
  
 1. PURCHASE AND SALE OF NOTES. 
  
 (a) Purchase of Notes. Subject to the satisfaction
(or waiver) of the conditions set forth in Section 6 below and the consummation of the matters set forth in Section 7 below, the Company shall issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the
Company on the Closing Date (as defined below), a principal amount of Notes as is set forth opposite such Buyer’s name on the Schedule of Buyers under the heading “Principal Amount”. 
  
 (b) Subscription and Closing. 
  
 (i) The deposit of the Notes and the Purchase Price (as
defined below) into escrow (the “Subscription”) shall occur on the Subscription Date at the offices of Morgan, Lewis & Bockius LLP, 1701 Market Street, Philadelphia, Pennsylvania 19103. The date and time of the Subscription (the
“Subscription Date”) shall be 10:00 a.m., New York City Time, immediately following notification of satisfaction (or waiver) of the conditions to the Subscription set forth in Section 6 below or on a date to be mutually agreed to by
the Company and each Buyer. 
  
 (ii) The closing
of the purchase of the Notes (the “Closing”) shall take place at such time as JPMorgan Chase Bank (the “Escrow Agent”) takes the Release Actions (as defined below). The date and time of the Closing shall be referred
to as the “Closing Date”. 
  
 (c) Purchase Price. The purchase price for each Buyer (the “Purchase Price”) of the Notes to be purchased by each such Buyer at the Closing shall be equal to $1.00 for each $1.00 of principal amount of Notes being
purchased by such Buyer at the Closing. 
  
 (d)
Subscription Deliveries. At the Subscription, (i) each Buyer shall deposit its Purchase Price (as set forth opposite such Buyer’s name on the Schedule of Buyers under the heading “Purchase Price”) for the Notes to be issued and
sold to such Buyer, by wire transfer of immediately available funds to the Escrow Agent pursuant to the terms of the Escrow Agreement to be entered into at the Subscription by the Company, each Buyer and the Escrow Agent substantially in the form of
Exhibit C hereto (the “Escrow Agreement”); (ii) the Company shall deliver to the Escrow Agent the Notes (in such principal amounts as such Buyer shall request), duly executed on behalf of the Company, dated as of the
Subscription Date and registered in the name of such Buyer or its designee; and (iii) the Company shall deliver to the Escrow Agent a completed and executed notice of redemption (the “Notice of Redemption”) pursuant to Article XI of
the Indenture notifying the Trustee of the Company’s intention to redeem all of the Existing Notes then outstanding, which Notice of Redemption will be undated and held by the Escrow Agent for release in accordance with the Escrow Agreement.
Until the Closing Date, title to the cash deposited by each Buyer shall remain vested in such Buyer and the Company shall not have any right, title or interest in such cash; provided that nothing in this sentence shall be deemed a waiver or
limitation of the contractual rights of the parties set forth in this Agreement or the other Transaction Documents. 
  

 2 

 2. BUYER’S REPRESENTATIONS AND WARRANTIES. 
  
 Each Buyer represents and warrants with respect to only
itself that: 
  
 (a) No Public Sale or
Distribution. Such Buyer is (i) acquiring the Notes, and (ii) upon conversion of the Notes will acquire the Conversion Shares issuable upon conversion of the Notes, for its own account and not with a view towards, or for resale in connection
with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the 1933 Act; provided, however, that by making the representations herein, such Buyer does not agree to hold any of the Securities
for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act. Such Buyer is acquiring the Securities hereunder in
the ordinary course of its business. Such Buyer presently does not have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Securities. For purposes of this Agreement, “Person” means an
individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. 
  
 (b) Accredited Investor Status. Such Buyer is an “accredited investor” (as that term is
defined in Rule 501(a) of Regulation D). Such Buyer, taking into account the personnel and resources it can practically bring to bear on the purchase of the Notes contemplated hereby, is knowledgeable, sophisticated and experienced in making, and is
qualified to make, decisions with respect to investments in debt and equity securities presenting an investment decision like that involved in the purchase of the Notes. Such Buyer is able to bear the economic risk of an investment in the
Securities. 
  
 (c) Reliance on
Exemptions. Such Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in
part upon the truth and accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Buyer set forth herein in order to determine the availability of such exemptions and
the eligibility of such Buyer to acquire the Securities. 
  
 (d) Information. Such Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the
Securities which have been requested by such Buyer. Such Buyer and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other due diligence investigations conducted by such Buyer or
its advisors, if any, or its representatives shall modify, amend or affect such Buyer’s right to rely on the Company’s representations and warranties contained herein. Such Buyer understands that its investment in the Securities involves a
high degree of risk. Such Buyer has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities. Such Buyer has, in connection with its
decision to purchase the Notes, relied solely upon the SEC Reports (as defined below) and the representations and warranties contained in the Transaction Documents (as defined below). 
  
 (e) No Governmental Review. Such Buyer understands that no United States federal or state agency or
any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the 

  

 3 

 
investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. 
  
 (f) Transfer or Resale. Such Buyer understands that
except as provided in the Registration Rights Agreement: (i) the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may not, directly or indirectly, be offered for sale, sold, assigned,
transferred or otherwise disposed unless (A) subsequently registered thereunder, (B) such Buyer shall have delivered to the Company an opinion of counsel reasonably acceptable to the Company, in a form and substance reasonably acceptable to the
Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, (C) transferred to an Affiliate (as defined in Rule 144, an
“Affiliate”) of such Buyer that certifies that it is an accredited investor or (D) such Buyer provides the Company with reasonable assurance, including any reasonably requested opinion of counsel, that such Securities can be sold,
assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act, as amended (or a successor rule thereto) (collectively, “Rule 144”); (ii) any sale of the Securities made in reliance on Rule 144 may be made
only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person) through whom the sale is made) may be deemed to be an underwriter (as that
term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other Person is under any obligation to register the
Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. 
  
 (g) Legends. Such Buyer understands that the certificates or other instruments representing the Notes and, until such time as the
resale of the Conversion Shares have been registered under the 1933 Act as contemplated by the Registration Rights Agreement, the stock certificates representing the Conversion Shares, except as set forth below, shall bear any legend as required by
the “blue sky” laws of any state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock certificates): 
  
 [NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE
SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE
OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) AN OPINION OF COUNSEL
REASONABLY ACCEPTABLE TO THE COMPANY, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE
SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. 
  

 4 

 The legend set forth above shall be removed and the Company shall issue a certificate
without such legend to the holder of the Securities upon which it is stamped, if, unless otherwise required by state securities laws, (i) upon transfer such Securities are registered for resale under the 1933 Act, (ii) in connection with a sale,
assignment or other transfer, such holder provides the Company with an opinion of counsel reasonably acceptable to the Company, in a form reasonably acceptable to the Company, to the effect that such legend is not required under the applicable
requirements of the 1933 Act, or (iii) such holder provides the Company with reasonable assurance that the Securities can be sold, assigned or transferred pursuant to Rule 144(k). 
  
 (h) Validity; Enforcement. This Agreement and each of the other Transaction Documents to which such
Buyer is a party has been duly and validly authorized, executed and delivered on behalf of such Buyer and shall constitute the legal, valid and binding obligations of such Buyer, enforceable against such Buyer in accordance with their respective
terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of
applicable creditors’ rights and remedies and except that the indemnification provisions under the Transaction Documents may further be limited by principles of public policy. 
  
 (i) No Conflicts. The execution, delivery and performance by such Buyer of this Agreement and each of
the other Transaction Documents to which such Buyer is a party and the consummation by such Buyer of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Buyer or (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to
which such Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Buyer, except in the case of clauses (ii) and (iii) above, for such
conflicts, defaults, rights or violations which, individually or in the aggregate, have not had, and would not reasonably be expected to have, a material adverse effect on the ability of such Buyer to perform its obligations hereunder. 

 
 (j) Residency. Such Buyer is a resident of that
jurisdiction specified below its address on the Schedule of Buyers. 
  
 (k) Beneficial Ownership. Schedule 2(k) sets forth such Buyer’s beneficial ownership of Common Stock as of the date hereof. 
  
 (l) Disclosure. No representation or warranty made by such Buyer in this Agreement, any schedule or
exhibit hereto, or any certificate delivered hereunder, when taken together, contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained herein or therein not misleading in light of
the circumstances under which they were made. 
  

 5 

 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 
  
 The Company hereby represents and warrants to each of the
Buyers as follows: 
  
 (a) Subsidiaries; Core
Partner Companies. 
  
 (i) The Company has no
wholly-owned Subsidiaries other than those listed on the Schedule 3(a)(i)(A). Except as disclosed in Schedule 3(a)(i)(B), the Company owns, directly or indirectly, the capital stock or comparable equity interests of each Subsidiary
free and clear of any Lien (as defined in Section 3(f) below) and all the issued and outstanding shares of capital stock or comparable equity interest of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights. For purposes of this Agreement, “Subsidiary” means those subsidiaries of the Company set forth in Schedule 3(a)(i)(A). 
  
 (ii) Schedule 3(a)(ii) sets forth a list of (1) each of the Core Partner Companies, (2) the number
and class of equity securities in each Core Partner Company and (3) to the knowledge of the Company, the percentage of each Core Partner Company’s voting interest owned by the Company, in the case of clauses (1), (2) and (3) as of December 31,
2003. Except as set forth in Schedule 3(a)(ii), since December 31, 2003, to the Company’s knowledge, (A) the Company has not sold any equity securities in a Private Core Partner Company (other than sales of equity securities of Private
Core Partner Companies after the date hereof that, individually or in the aggregate, are not material to the Company) and (B) the percentage of each Private Core Partner Company’s voting interest owned by the Company has not been materially
reduced. For purposes of this Agreement, the terms “Core Partner Company”, “Private Core Partner Company” and “Emerging Partner Company” shall each have the respective meaning used by the Company
for such term in the Company’s SEC Report on Form 10-K for the year ended December 31, 2003 filed with the SEC on March 15, 2004 (the “2003 Form 10-K”)). 
  
 (b) Organization and Qualification. Each of the Company and the Subsidiaries is an entity duly
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite power and authority to own and use its properties and assets and to carry on its business as
currently conducted. Neither the Company nor any Subsidiary is in violation of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the
Subsidiaries is duly qualified to do business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the case may be, do not and could not, individually or in the aggregate, (i) materially adversely affect the legality, validity or enforceability of any of the material provisions of the
Transaction Document, (ii) reasonably be expected to have or result in a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole on a
consolidated basis, or (iii) materially adversely impair the Company’s ability to perform fully on a timely basis its material obligations under any of the Transaction Documents (any of (i), (ii) or (iii), a “Material Adverse
Effect”); provided, however, that none of the following shall be deemed, either alone or in combination, to constitute, and none of the following shall be taken into account in determining whether there has been, or will be, a

  

 6 

 
Material Adverse Effect: (a) any adverse change, effect, event, occurrence, state of facts or development attributable to the announcement or pendency of the
transactions contemplated by this Agreement; or (b) any adverse change, effect, event, occurrence, state of facts or development resulting from or relating to compliance with the terms of, or the taking of any action required by, this Agreement. For
purposes of this Agreement, “Transaction Documents” means, collectively, this Agreement, the Notes, the Registration Rights Agreement, the Escrow Agreement, the Irrevocable Transfer Agent Instructions (as defined in Section 5(b) and
each of the other documents entered into or delivered by the parties hereto in connection with the transactions contemplated by this Agreement. 
  
 (c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction Documents to which it is a party by the
Company and the consummation by it of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Notes, the reservation for issuance of the Conversion Shares issuable upon conversion of the Notes and the
issuance of the Conversion Shares upon conversion of the Notes, have been duly authorized by all necessary action on the part of the Company and no further consent or action is required by the Company, its Board of Directors or its stockholders.
Each of the Transaction Documents has been (or, if executed after the date hereof, upon delivery will be) duly executed by the Company and is, or when delivered in accordance with the terms hereof, will constitute, the legal, valid and binding
obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except that the indemnification provisions under the Transaction Documents may further be limited by principles of
public policy. 
  
 (d) No Conflicts. The
execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Notes and the reservation for
issuance of the Conversion Shares issuable upon conversion of the Notes, do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other
organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a debt of the Company or a Subsidiary or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, except to the extent that such conflict, default or termination right has not had, and could not reasonably be expected to have, a Material Adverse
Effect, or (iii) except as set forth in Schedule 3(d), result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is
subject (including federal and state securities laws and regulations and the rules and regulations of the Nasdaq SmallCap Market (the “Principal Market”) or any other self-regulatory organization to which the Company 

  

 7 

 
or its securities are subject), or by which any property or asset of the Company or a Subsidiary is bound or affected, except to the extent that such
violation has not had, and could not reasonably be expected to have, a Material Adverse Effect. 
  
 (e) Consents. Except as disclosed in Schedule 3(e), neither the Company nor any of its Subsidiaries is required to obtain
any consent, authorization or order of, or make any filing or registration with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for the Company to execute, deliver or perform any of its
obligations under or contemplated by the Transaction Documents, in each case in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the Company or any of its Subsidiaries is required to
obtain pursuant to the preceding sentence have been obtained or effected on or prior to the Subscription Date. The Company and its Subsidiaries are unaware of any facts or circumstances which might prevent the Company from obtaining or effecting any
of the foregoing. 
  
 (f) Issuance of the
Securities. The Securities are duly authorized and, when issued and paid for in accordance with the Transaction Documents, will be duly and validly issued, fully paid and nonassessable (if applicable), free and clear of all liens, charges,
claims, security interests, encumbrances, rights of first refusal or other restrictions (“Liens”) and shall not be subject to preemptive rights or similar rights of stockholders. As of the Subscription, the Company shall have
reserved from its duly authorized capital stock not less than 150% of the maximum number of shares of Common Stock issuable upon conversion of the Notes (assuming for purposes hereof, that the Notes are convertible at the Conversion Price (as
defined in the Notes) and without taking into account any limitations on the conversion of the Notes set forth in the Notes). 
  
 (g) Dilutive Effect. The Company understands and acknowledges that the number of Conversion Shares issuable upon conversion of the
Notes will increase in certain circumstances. Except as provided in the Notes, the Company further acknowledges that its obligation to issue Conversion Shares upon conversion of the Notes in accordance with this Agreement and the Notes is not
conditioned on the dilutive effect that such issuance may have on the ownership interests of other stockholders of the Company. Furthermore, the Company understands and acknowledges that the Transaction Documents do not in any manner preclude any
Buyer from trading or otherwise transacting in the Common Stock or any other security of the Company at any time from and after the Execution 8-K Filing (as defined in Section 4(h) below) with the SEC, including during the Interest Measuring Period
(as defined in the Notes). 
  
 (h)
Capitalization. As of the date hereof, the capital stock of the Company consists of 2,010,000,000 shares, 2,000,000,000 shares of which are Common Stock, and 10,000,000 shares of which are preferred stock, $0.01 par value per share. As of the
date hereof, there were 761,132,009 shares of Common Stock issued and outstanding. There were no shares of preferred stock outstanding on the date hereof. All outstanding shares of capital stock are duly authorized, validly issued, fully paid and
nonassessable and have been issued in compliance with all applicable securities laws. Except as disclosed in Schedule 3(h), there are no outstanding options, warrants, script rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of 

  

 8 

 
Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional
shares of Common Stock, or securities or rights convertible or exchangeable into shares of Common Stock. The issue and sale of the Securities (including the Conversion Shares) will not obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Buyers) and will not result in a right of any holder of securities of the Company to adjust the exercise, conversion, exchange or reset price under such securities. To the knowledge of the Company, as of the
date hereof, no Person or group of related Persons beneficially owns (as determined pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “1934 Act”)), or has the right to acquire, by agreement with or by
obligation binding upon the Company, beneficial ownership of in excess of 5% of the outstanding Common Stock, ignoring for such purposes any limitation on the number of shares of Common Stock that may be owned at any single time. 
  
 (i) SEC Reports; Financial Statements. The Company
has filed all reports required to be filed by it under the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (the foregoing materials (together with any materials filed by the Company under
the 1934 Act, whether or not required) being collectively referred to herein as the “SEC Reports” and, together with this Agreement and the Schedules to this Agreement, the “Disclosure Materials”) on a timely basis
or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. The Company has delivered to each Buyer or their respective representatives true, correct and complete copies
of the SEC Reports not available on the EDGAR system, other than filings made pursuant to the rules and regulations promulgated under Section 16 of the Exchange Act. Except as set forth in Schedule 3(i), as of their respective dates, the SEC
Reports complied in all material respects with the requirements of the 1933 Act and the 1934 Act and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Except as set forth in Schedule 3(i),
the financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Except as
set forth in Schedule 3(i), such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as
may be otherwise specified in such financial statements or the notes thereto, and fairly present the financial position of the Company and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for
the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments and the omission of certain footnotes. All material agreements to which the Company or any Subsidiary is a party or to which the property or
assets of the Company or any Subsidiary are subject are included as part of or specifically identified in the SEC Reports to the extent required by the rules and regulations of the SEC as in effect at the time of filing. 
  
 (j) Material Changes. 
  

 9 

 (i) Since the date of the audited financial statements included in the 2003 Form 10-K,
except as specifically disclosed in the 2003 Form 10-K or in Schedule 3(j)(i), (A) there has been no event, occurrence or development that, individually or in the aggregate, has resulted in, or that could reasonably be expected to result in,
a Material Adverse Effect, (B) the Company has not incurred any liabilities (contingent or otherwise) other than (1) transactions in the ordinary course of business consistent with past practice (including, without limitation, investments in and
incurrence of obligations on behalf of new or existing partner companies in the ordinary course of business consistent with past practice) and (2) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP
or required to be disclosed in filings made with the SEC, (C) the Company has not altered its method of accounting or the identity of its auditors, except as disclosed in its SEC Reports, (D) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, (E) the Company has not sold any assets, individually or in the aggregate, in excess of
$50,000 (other than (x) sales of equity securities of Emerging Partner Companies that, individually or in the aggregate, are not material to the Company and (y) sales of equity securities of Private Core Partner Companies after the date hereof that,
individually or in the aggregate, are not material to the Company) and (F) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock-based plans. 
  
 (ii) Since December 31, 2003, except as specifically
disclosed in Schedule 3(j)(ii), to the knowledge of the Company, no event, occurrence or development has occurred with respect to a Core Partner Company that, individually or in the aggregate, has resulted in, or could reasonably be expected
to result in, a Material Adverse Effect. 
  
 (k)
Indebtedness. 
  
 (i) Except for the
Existing Notes (as defined below) and as disclosed in Schedule 3(k), neither the Company nor any of its Subsidiaries has any outstanding Indebtedness in excess of $100,000 in the aggregate. Except for the Existing Notes and as disclosed in
Schedule 3(k), no Indebtedness of the Company individually in excess of $100,000 is senior to or ranks pari passu with the Notes in right of payment, whether with respect of payment of redemptions, interest, damages or upon liquidation
or dissolution or otherwise. Schedule 3(k) sets forth the aggregate principal amount of Existing Notes outstanding as of the date hereof. 
  
 (ii) For purposes of this Agreement: (x) “Existing Notes” means the 51⁄2% Convertible Subordinated Notes due 2004
issued pursuant to the Indenture, dated as of December 21, 1999 (the “Indenture”), between the Company and Chase Manhattan Trust Company, National Association, as trustee (the “Trustee”); (y)
“Indebtedness” of any Person means, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property or services (other than trade payables
entered into in the ordinary course of business), (C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar
instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as
financing, in either case with respect to any property or assets acquired with the 

  

 10 

 
proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to
repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement which, in accordance with GAAP, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured
by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in any property or assets (including accounts and contract rights) owned by any Person, even though the Person which
owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through (G) above; and
(z) “Contingent Obligation” means, as to any Person, any known direct or indirect liability, contingent or otherwise, of that Person with respect to any Indebtedness, of another Person. 
  
 (l) Absence of Litigation. Except as disclosed in the
2003 Form 10-K, there is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or
affecting the Company or any of its Subsidiaries that, individually or in the aggregate, has resulted in, or could reasonably be expected to result in, a Material Adverse Effect. 
  
 (m) Compliance. 
  
 (i) Neither the Company nor any Subsidiary (i) is in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received written notice of a claim that it is in default under or
that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in
violation of any order of any court, arbitrator, governmental body or exchange or automated quotation system on which any of the securities of the Company are listed or designated, or (iii) is or has been in violation of any statute, rule or
regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor
matters, except in each case as, individually or in the aggregate, has not had or resulted in, or could not reasonably be expected to have or result in, a Material Adverse Effect. 
  
 (ii) To the knowledge of the Company, none of the Core Partner Companies (i) is in violation of any order of
any court, arbitrator, governmental body or exchange or automated quotation system on which any of the securities of such Core Partner Company is listed or designated, or (ii) is or has been in violation of any statute, rule or regulation of any
governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each
case as, individually or in the aggregate, has not had or resulted in, or could not reasonably be expected to have or result in, a Material Adverse Effect. 
  

 11 

 (n) Title to Assets. The Company and the Subsidiaries do not own real property and
have good and marketable title to all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for Liens that do not materially affect the value of such
property, do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and, individually or in the aggregate, has not had or resulted in, and could not reasonably be expected to have or
result in, a Material Adverse Effect. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases of which the Company and the Subsidiaries are in compliance
except, in each case, as do not result in, and could not reasonably be expected to result in, a Material Adverse Effect. 
  
 (o) Certain Fees. Except as set forth in Schedule 3(o), no brokerage or finder’s fees or commissions or any other
payment, whether in the form of cash, securities or other consideration, or any combination of the foregoing, are or will be payable, directly or indirectly, by the Company, any Subsidiary or any Affiliate thereof to any broker, financial advisor or
consultant, finder, placement agent, investment banker, bank or other Person directly or indirectly with respect to the transactions contemplated by this Agreement or any of the other Transaction Documents, and the Company has not taken any action
that would cause any Buyer to be liable for any such fees or commissions pursuant to any agreement or arrangement to which the Company is a party. The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense
(including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any claim against any Buyer relating to the fees set forth on Schedule 3(o) or a breach of this representation. 
  
 (p) Private Placement. Neither the Company nor any
Person acting on the Company’s behalf has sold or offered to sell or solicited any offer to buy the Securities by means of any form of general solicitation or advertising. Neither the Company nor any of its Affiliates nor any person acting on
the Company’s behalf has, directly or indirectly, at any time within the past six months, made any offer or sale of any security or solicitation of any offer to buy any security of the Company under circumstances that would (i) eliminate the
availability of the exemption from registration under Regulation D in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii) cause the offering of the Securities pursuant to the Transaction Documents to be
integrated with prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system on which
any of the securities of the Company are listed or designated. None of the Company, its Subsidiaries, their Affiliates and any Person acting on their behalf will take any action or steps referred to in the preceding sentence that would require the
registration of any of the Securities under the 1933 Act or cause the offering to be integrated with the other offerings for purposes of any applicable law, regulation or stockholder approval provisions. The Company is not, and is not an Affiliate
of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company is not a United States real property holding corporation within the meaning of the Foreign Investment in Real Property Tax Act of
1980. No consent, license, permit, waiver approval or authorization of, or designation, declaration, registration or filing with, the SEC or any state securities regulatory authority is required in connection with the 

  

 12 

 
offer, sale, issuance or delivery of the Securities, other than the possible filing of a Form D with the SEC. 
  
 (q) Form S-3 Eligibility. The Company is eligible to
register the Conversion Shares and the Interest Shares for resale by the Buyers using Form S-3 promulgated under the 1933 Act. 
  
 (r) Listing and Maintenance Requirements. Except as set forth in Schedule 3(r), since December 31, 2003, the Company has
been in compliance with all listing and maintenance requirements for the Principal Market. Except as set forth in Schedule 3(r), the Company has no knowledge of any facts or circumstances which would reasonably lead to delisting or suspension
of the Common Stock by the Principal Market in the foreseeable future. Except as set forth in Schedule 3(r), since December 31, 2003, the Company has not received any communication, written or oral, from the SEC or the Principal Market
regarding the suspension or delisting of the Common Stock from the Principal Market. 
  
 (s) Registration Rights. Except as set forth in Schedule 3(s), the Company has not granted or agreed to grant to any Person
any rights (including “piggy-back” registration rights) to have any securities of the Company registered with the SEC or any other governmental authority that have not been satisfied. 
  
 (t) Application of Takeover Protections. Assuming the
accuracy of the information set forth on Schedule 2(k), there is no control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the
Company’s charter documents or the laws of its state of incorporation that is or could become applicable to any of the Buyers solely as a result of the Buyers and the Company fulfilling their obligations or exercising their rights under the
Transaction Documents, including, without limitation, as a result of the Company’s issuance of the Securities and the Buyers’ ownership of the Securities. 
  
 (u) Disclosure. The Company confirms that it has not provided any of the Buyers or their counsel with
any information that constitutes or might constitute material, nonpublic information. The Company understands and confirms that each of the Buyers will rely on the foregoing representations in effecting transactions in securities of the Company. The
SEC Reports and the representations and warranties set forth in the Transaction Documents regarding the Company, its business and the transactions contemplated hereby, including the Schedules to this Agreement, furnished by or on behalf of the
Company, when taken together, contains any untrue statement of material fact or omit to state a material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The
Company acknowledges and agrees that no Buyer makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in this Agreement. 
  
 (v) Acknowledgment Regarding Buyers’ Purchase of
Company Securities. The Company acknowledges and agrees that each of the Buyers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby.
The Company further acknowledges that no Buyer is acting 

  

 13 

 
as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated
hereby and thereby and any advice given by any Buyer or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Buyers’
purchase of the Securities. The Company further represents to each Buyer that the Company’s decision to enter into the Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby and thereby
by the Company and its representatives. 
  
 (w)
Intellectual Property. Except as disclosed in 2003 Form 10-K, to the knowledge of the Company, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks,
trade names, copyrights, licenses and other similar rights that are necessary or material for use in connection with each of such companies operations as currently conducted and which the failure to so has had, or could reasonably be expected to
have, a Material Adverse Effect (collectively, the “Intellectual Property Rights”). Neither the Company nor any Subsidiary has received a written notice that the Intellectual Property Rights used by the Company or any Subsidiary
violates or infringes upon the rights of any Person except as may be described in the 2003 Form 10-K or as does not result in, and could not reasonably be expected to result in, a Material Adverse Effect. To the knowledge of the Company, all such
Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights, in each case except as may be described in the 2003 Form 10-K or as does not result in, and could not
reasonably be expected to result in, a Material Adverse Effect. 
  
 (x) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to
conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits, individually or in the aggregate, has not had or resulted in, and could not reasonably be expected to have or result in, a
Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any written notice of proceedings relating to the revocation or modification of any Material Permit except as described in the SEC
Reports or as has not resulted in, and could not reasonably be expected to result in, a Material Adverse Effect. 
  
 (y) Transactions With Affiliates and Employees. Except as set forth in the SEC Reports or in Schedule 3(y), none of the
officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors)
exceeding $60,000, including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 
  
 (z) Insurance. The Company and the Subsidiaries are
insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are 

  

 14 

 
engaged. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business. 
  
 (aa) Solvency. Based on the financial condition of the Company as of the Subscription Date, both prior to and after giving
effect to the transactions contemplated by this Agreement to occur on the Closing Date, (i) the Company’s fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing
debts and other liabilities (including known contingent liabilities) as they mature; and (ii) the current liquid assets of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into
account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. To the Company’s knowledge, the Company has not incurred any debts beyond its ability to
pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). 
  
 (bb) Internal Accounting Controls. The Company and the Subsidiaries maintain a system of internal accounting controls materially
sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for
assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 
  
 (cc) Tax Status. The Company and each of the Subsidiaries (i) has made or filed all federal and state income and all other tax
returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and
declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction. 
  
 (dd) Employee Relations. Neither the Company nor any of the Subsidiaries is a party to any collective bargaining agreement or
employs any member of a union. The Company and the Subsidiaries believe that their relations with their employees are good. No executive officer of the Company (as defined in Rule 501(f) of the 1933 Act) has notified the Company that such officer
intends to leave the Company or otherwise terminate such officer’s employment with the Company. No executive officer of the Company, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any
employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each such executive officer does not
subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. 
  

 15 

 (ee) Sarbanes-Oxley Act. The Company is in material compliance with all applicable
requirements of the Sarbanes-Oxley Act of 2002 and all applicable rules and regulations promulgated by the SEC thereunder, in each case, which are currently applicable to it. 
  
 4. COVENANTS. 
  
 (a) Reasonable Best Efforts. Each party shall use its reasonable best efforts timely to satisfy each of the conditions to be
satisfied by it as provided in Sections 6 and 7 of this Agreement. 
  
 (b) Form D and Blue Sky. The Company agrees to file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to each Buyer promptly after such filing. The Company
shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities for sale to the Buyers at the Closing pursuant to this Agreement under applicable securities or “Blue
Sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Buyers on or prior to the Subscription Date to the extent action is required prior
to the Closing. The Company shall make all filings and reports relating to the offer and sale of the Securities required under applicable securities or “Blue Sky” laws of the states of the United States following the Subscription Date.

  
 (c) Reporting Status. Until the date
on which none of the Notes are outstanding, the Company shall file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even
if the 1934 Act or the rules and regulations thereunder would otherwise permit such termination; provided that nothing in this Section 4(c) shall relieve the Company of its obligations under the Registration Rights Agreement.

  
 (d) Use of Proceeds; Redemption of the
Existing Notes.  
  
 (i) The Company
will use the proceeds from the sale of the Securities for the redemption of the Existing Notes as contemplated by Section 4(d)(ii) and Section 7. Any proceeds remaining after such redemption of the Existing Notes may be used by the Company only for
(A) general working capital purposes and (B) the acquisition of interests in existing and new partner companies. For the purposes of clarity, except for the redemption of the Existing Notes as specifically provided in this Section 4(d) and Section
7, the Company shall not use the proceeds from the sale of the Securities to pay dividends to, redeem or purchase any junior securities of the Corporation. 
  
 (ii) As soon as practicable following the Closing Date, the Company shall use its best efforts to redeem and retire all of the Existing
Notes then outstanding. In furtherance of the foregoing, the Company shall use its best efforts (including, without limitation, taking and causing the Trustee to take, all actions required by the Indenture) to cause the redemption of the Existing
Notes to be consummated as soon as practicable following Closing Date. 
  
 (e) Listing Matters. 
  

 16 

 (i) General. The Company shall use its reasonable best efforts to maintain the
Common Stock’s authorization for quotation on the Principal Market. In the event that the Company is unable to maintain its Common Stock’s authorization for quotation on the Principal Market, the Company shall use its reasonable best
efforts to cause its Common Stock to be listed or quoted on any of the Nasdaq National Market, the New York Stock Exchange or the American Stock Exchange (the “Other Markets”). 
  
 (ii) Reverse Stock Split. The Company shall use its
reasonable best efforts to provide each stockholder entitled to vote at the next meeting of stockholders of the Company, which meeting shall be held no later than April 23, 2004, a proxy statement, soliciting each such stockholder’s affirmative
vote at such stockholder meeting for approval of granting the Company’s Board of Directors discretionary authority to effect a reverse stock split (the “Reverse Stock Split”) designed to cure the Company’s minimum bid
deficiency and maintain its listing on the Principal Market, which approval (the “Reverse Stock Split Approval”) will require the approval of the holders of two-thirds of the outstanding shares of Common Stock. The Company’s
Board of Directors has recommended to the Company’s stockholders that they approve such proposal and engaged DF King as its proxy solicitor in connection with the Reverse Stock Split. The Company shall not intentionally or willfully take or
omit to take any reasonable or customary action that could reasonably be expected to prevent or delay its receipt of the Reverse Stock Split Approval. 
  
 (iii) Stockholder Approval of the Issuance of the Securities. The Company shall use its reasonable best efforts to provide each
stockholder entitled to vote at the first meeting of its stockholders held following its 2004 annual meeting of stockholders, a proxy statement, which has been previously reviewed by the Buyers and Morgan, Lewis & Bockius LLP, soliciting each
such stockholder’s affirmative vote at such stockholder meeting for approval of the Company’s issuance of all of the Securities as described in the Transaction Documents in accordance with applicable law and the rules and regulations of
the Principal Market and the Company shall use its reasonable best efforts to solicit its stockholders’ approval of such issuance of the Securities. 
  
 (iv) Listing of Registrable Securities. The Company shall use its reasonable best efforts to promptly secure the listing of all of
the Registrable Securities (as defined in the Registration Rights Agreement) (other than the Notes) upon each national securities exchange and automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official
notice of issuance) and shall use its reasonable best efforts to maintain, so long as any other shares of Common Stock shall be so listed, such listing of all Registrable Securities (other than the Notes) from time to time issuable under the terms
of the Transaction Documents. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section 4(e)(iii). 
  
 (f) Fees. Subject to Section 8 below, at the Subscription upon submission of evidence of expenditure thereof, the Company shall pay
to Morgan, Lewis & Bockius LLP an amount not to exceed $50,000 for (i) reimbursement of reasonable legal fees incurred in connection with the transactions contemplated by the Transaction Documents and (ii) reasonable expenses of legal counsel
incurred in connection with the transactions contemplated by the Transaction Documents so long as bills evidencing such fees and expenses have been received 

  

 17 

 
by the Company. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or broker’s commissions
relating to or arising out of the transactions contemplated hereby for placement agents, financial advisors or brokers engaged by the Company or its Affiliates or agents (including, without limitation, those fees set forth on Schedule 3(o)).
The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorney’s fees and out-of-pocket expenses) arising in connection with any claim relating to any such
payment. Except as otherwise set forth in the Transaction Documents, each party to this Agreement shall bear its own expenses in connection with the sale of the Securities to the Buyers. 
  
 (g) Pledge of Securities. The Company acknowledges and agrees that the Securities may be pledged by
an Investor (as defined in the Registration Rights Agreement) in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer,
sale, assignment or other disposition of the Securities hereunder, and no Investor effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this
Agreement or any other Transaction Document, including, without limitation, Section 2(f) of this Agreement; provided that an Investor and its pledgee shall be required to comply with the provisions of Section 2(f) hereof in order to effect a
sale, transfer or assignment of Securities to such pledgee. The Company hereby agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the Securities to such pledgee by an
Investor. 
  
 (h) Disclosure of Transactions
and Other Material Information. No later than one Business Day following the date hereof, the Company shall file a Current Report on Form 8-K (which has been previously reviewed by the Buyers and Morgan, Lewis & Bockius LLP) in the form
required by the 1934 Act (including all attachments, the “Execution 8-K Filing”) and attaching the press release that will be issued by the Company disclosing the transaction (provided that Langley Capital, L.P., as a representative
of the Buyers, shall be consulted by the Company in connection with such press release prior to its release). No later than one Business Day following the Subscription Date, the Company shall file a Current Report on Form 8-K (which has been
previously reviewed by the Buyers and Morgan, Lewis & Bockius LLP) describing the terms of the transactions contemplated by the Transaction Documents in the form required by the 1934 Act, and attaching the material Transaction Documents
(including, without limitation, this Agreement (including the form of the Notes, the Registration Rights Agreement and the Escrow Agreement (other than the Schedules to the Escrow Agreement)) as exhibits to such Form 8-K (including all attachments,
the “Subscription 8-K Filing”). No later than one Business Day following the Closing Date, the Company shall file a Current Report on Form 8-K (which has been previously reviewed by the Buyers and Morgan, Lewis & Bockius LLP)
describing the consummation of the transactions contemplated by the Transaction Documents in the form required by the 1934 Act (the “Closing 8-K Filing”). Subject to the foregoing, neither the Company nor any Buyer shall issue any
press releases or any other public statements with respect to the transactions contemplated hereby; provided, however, that the Company shall be entitled, without the prior approval of any of the Buyers, to make any press release or
other public disclosure with respect to such transactions (i) in substantial conformity with the Subscription 8-K Filing and Closing 8-K Filing and contemporaneously therewith, (ii) as is required by applicable law and regulations or (iii) to
explain the Company’s reasons for and 

  

 18 

 
business analysis behind the transactions contemplated by this Agreement and the impact of such transactions on the Company’s business (provided that in
the case of clause (i) Langley Capital, L.P., as a representative of the Buyers, shall be consulted by the Company in connection with any press release prior to its release). As used herein, “Business Day” means any day other than
Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed. 
  
 (i) Corporate Existence. The Company will do or cause to be done all things necessary to preserve and keep in full force and effect
its corporate existence, rights (charter and statutory) and franchises, except to the extent that the board of directors shall determine that the failure to does not have, and could not reasonable be expected to have, a Material Adverse Effect;
provided, however, that the Company shall not be required to preserve any right or franchise if the board of directors shall determine that the preservation thereof is no longer desirable in the conduct of the business of the company
and that the loss thereof is not disadvantageous in any material respect to the holders. 
  
 (j) Payment of Taxes and Other Claims. The Company will pay or discharge or cause to be paid or discharged, before the same shall
become delinquent, (1) all taxes, assessments and governmental charges levied or imposed upon it or any Subsidiary or upon the income, profits or property of the Company or any Subsidiary, and (2) all lawful claims for labor, materials and supplies
which, if unpaid, becomes, or could reasonably be expected to become, a lien upon the property of the Company or any Subsidiary and have, or be reasonably expected to have, a Material Adverse Effect; provided, however, that the Company
shall not be required to pay or discharge or cause to be paid or discharged any such tax, assessment, charge or claim whose amount, applicability or validity is being contested in good faith by appropriate proceedings. 
  
 (k) Waiver of Certain Covenants. The Company may omit
in any particular instance to comply with any term, provision or condition set forth in this Section 4, if before the time for such compliance the holders of at least a majority in principal amount of all outstanding Notes, either waive such
compliance in such instance or generally waive compliance with such covenant or condition, but no such waiver shall extend to or affect such covenant or condition except to the extent so expressly waived, and, until such waiver shall become
effective, the obligations of the Company in respect of any such term, provision or condition shall remain in full force and effect. 
  
 (l) Sale of Conversion Shares and Interest Shares. 
  
 (i) Each Buyer hereby agrees not to sell any of the Conversion Shares or Interest Shares under a
Registration Statement without effectively causing the prospectus delivery requirement under the Securities Act to be satisfied. 
  
 (ii) Each Buyer agrees to notify promptly the Company of the sale of all of its Conversion Shares and Interest Shares issued or issuable
to such Buyer. 
  
 (m) Restriction on
Redemption of Existing Notes. Until this Agreement is terminated in accordance with its terms, the Company shall not, directly or indirectly, repurchase 

  

 19 

 
or redeem any of the Existing Notes, including, without limitation, any exchange of Existing Notes for Common Stock or other securities of the Company except
as specifically provided in Section 4(d) and Section 7. 
  
 5.
REGISTER; TRANSFER AGENT INSTRUCTIONS. 
  
 (a) Register. The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate by notice to each holder of Notes), a register for the Notes, in which the Company shall
record the name and address of the Person in whose name the Notes have been issued (including the name and address of each transferee) and the principal amount of Notes held by such Person. The Company shall keep the register open and available at
all times during its business hours for inspection by any Buyer or its legal representatives. 
  
 (b) Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent, and any subsequent
transfer agent, to issue certificates or credit shares to the applicable balance accounts at The Depository Trust Company (“DTC”), registered in the name of each Buyer or its respective nominee(s), for the Conversion Shares and the
Interest Shares, if any, in such amounts as specified from time to time by each Buyer to the Company upon conversion of the Notes in the form of Exhibit D attached hereto (the “Irrevocable Transfer Agent Instructions”). The
Company warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5(b), and stop transfer instructions to give effect to Section 2(g) hereof, will be given by the Company to its transfer agent,
and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the other Transaction Documents. If a Buyer effects a sale, assignment or transfer of the
Securities in accordance with Section 2(f), the Company shall permit the transfer in accordance with the provisions of this Agreement and shall promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable
balance accounts at DTC in such name and in such denominations as specified by such Buyer to effect such sale, transfer or assignment. In the event that such sale, assignment or transfer involves Conversion Shares or Interest Shares sold, assigned
or transferred pursuant to an effective registration statement or pursuant to Rule 144, the transfer agent shall issue such Securities to the Buyer, assignee or transferee, as the case may be, without any restrictive legend. The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to a Buyer. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5(b) will be inadequate and agrees, in the event
of a breach or threatened breach by the Company of the provisions of this Section 5(b), that a Buyer shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate
issuance and transfer, without the necessity of showing economic loss and without any bond or other security being required. 
  
 6. CONDITIONS TO SUBSCRIPTION. 
  
 (a) Conditions to the Company’s Obligations. The obligation of the Company hereunder to issue and deposit the Notes with the
Escrow Agent at the Subscription is subject to the satisfaction, at or before the Subscription Date, of each of the following conditions, provided 

  

 20 

 
that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing each Buyer
with prior written notice thereof: 
  
 (i) Each
of the Buyers shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Company. 
  
 (ii) Each of the Buyers shall have delivered to the Escrow Agent the Purchase Price for the Notes being purchased by such Buyer at the
Closing by wire transfer of immediately available funds pursuant to the wire instructions provided by the Company. 
  
 (iii) The representations and warranties of each Buyer contained in the Transaction Documents shall be true and correct in all material
respects as of the Subscription Date with the same effect as though such representations and warranties were made at and as of the Subscription Date (other than any representation or warranty that is expressly made as of a specified date, which
shall be true and correct in all material respects as of such specified date only), and each Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be
performed, satisfied or complied with by such Buyer at or prior to the Subscription Date. The Company shall have received a certificate, executed by an authorized person of each Buyer, dated as of the Subscription Date, to (I) the foregoing effect
and (ii) setting forth such Buyer’s beneficial ownership of Common Stock as of the Subscription Date, in the form attached hereto as Exhibit E. 
  
 (iv) The applicable period following the Company’s filing with the Principal Market of the “Notification Form: Listing of
Additional Securities” on March 23, 2004 shall have expired under NASD Rule 4310(c)(17) and there shall have been no correspondence from the Principal Market requesting the Company to change the terms of the transactions contemplated by this
Agreement or prohibiting such transactions from occurring. 
  
 (b) Conditions to each Buyer’s Obligation. The obligation of each Buyer hereunder to deposit its Purchase Price with the Escrow Agent at the Subscription is subject to the satisfaction, at or before the
Subscription Date, of each of the following conditions, provided that these conditions are for each Buyer’s sole benefit and may be waived by such Buyer at any time in its sole discretion by providing the Company with prior written notice
thereof: 
  
 (i) The Company shall have executed
and delivered (A) to such Buyer each of the Transaction Documents and (B) to the Escrow Agent the Notes (in such principal amounts as such Buyer shall request) which are being purchased by such Buyer at the Closing pursuant to this Agreement, which
Notes shall be dated as of the Subscription Date. 
  
 (ii) Such Buyer shall have received the opinion of Dechert LLP, the Company’s counsel, dated as of the Subscription Date, in form, scope and substance reasonably satisfactory to such Buyer and in substantially the form of Exhibit
F attached hereto. 
  
 (iii) The Company
shall have delivered to such Buyer a copy of the Irrevocable Transfer Agent Instructions, in the form of Exhibit D attached hereto, which instructions shall have been delivered to and acknowledged in writing by the Company’s transfer
agent. 
  

 21 

 (iv) The Company shall have delivered to such Buyer a certificate evidencing the
incorporation and good standing of the Company issued by the Secretary of State of the State of Delaware as of a date within 10 days of the Subscription Date. 
  

(v) The Company shall have delivered to such Buyer a certified copy of the Certificate of Incorporation as certified by the Secretary
of State of the State of Delaware within 10 days of the Subscription Date. 
  
 (vi) The Company shall have delivered to such Buyer a certificate, in the form attached hereto as Exhibit G, executed by the Secretary of the Company and dated as of the Subscription Date, as to (i) the
resolutions consistent with Section 3(c) as adopted by the Company’s Board of Directors in a form reasonably acceptable to such Buyer (the “Resolutions”), (ii) the Certificate of Incorporation and (iii) the Bylaws, each as in
effect at the Subscription. 
  
 (vii) The
representations and warranties of the Company contained in the Transaction Documents shall be true and correct in all material respects (except that any representation warranty that is qualified by materiality or Material Adverse Effect shall be
true and correct in all respects) at and as of the Subscription with the same effect as though such representations and warranties were made at and as of the Subscription (other than any representation or warranty that is expressly made as of a
specified date, which shall be true and correct in all material respects (or in the case of any representation and warranty that is qualified by materiality or Material Adverse Effect shall be true and correct in all respects) as of such specified
date only), and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or
prior to the Subscription Date. Each Buyer shall have received a certificate, executed by the Chief Executive Officer of the Company, dated as of the Subscription Date, to the foregoing effect in the form attached hereto as Exhibit H.

  
 (viii) The Company shall have delivered to
such Buyer a letter from the Company’s transfer agent certifying the number of shares of Common Stock outstanding as of a date within five days of the Subscription Date. 
  
 (ix) The Common Stock (I) shall be designated for quotation or listed on an Eligible Market and (II) shall
not have been suspended by the SEC, as of the Subscription Date, or the applicable Eligible Market from trading on the applicable Eligible Market nor shall suspension by the SEC or, other than as set forth on Schedule 3(r), the applicable
Eligible Market have been threatened, as of the Subscription Date, either (A) in writing by the SEC or the applicable Eligible Market or (B) by falling below the minimum listing maintenance requirements of the applicable Eligible Market other than
the minimum bid requirements. 
  
 (x) The Company
shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the sale of the Notes. 
  

 22 

 (xi) The Company shall have delivered to such Buyer such other documents relating to the
transactions contemplated by this Agreement as such Buyer or its counsel may reasonably request. 
  
 (xii) The Company shall have paid to the Escrow Agent the escrow agent fees contemplated by Section 7(c) of the Escrow Agreement.

  
 (xiii) The Company shall have paid to Morgan,
Lewis & Bockius LLP the payments described in Section 4(f) above. 
  
 7. CLOSING MATTERS. 
  
 (a)
Reverse Stock Split Approval. The provisions set forth in this Section 7(a) shall only apply if the Reverse Stock Split Approval is received prior to April 30, 2004. 
  
 (i) Promptly following the Company’s receipt of the Reverse Stock Split Approval (and, in any event, no
later than May 10, 2004) the Company shall effect the Reverse Stock Split in a manner and at a ratio that is reasonably expected to enable the Company to promptly cure its minimum bid deficiency and maintain its listing on the Principal Market. In
connection with the foregoing, no later than May 10, 2004, the Company shall file with the Secretary of State of the State of Delaware an amendment to its Certificate of Incorporation effecting the Reverse Stock Split (the “Certificate of
Incorporation Amendment”), which Certificate of Incorporation Amendment will be effective no later than the close of business on the day of the filing. 
  
 (ii) Immediately following the effectiveness of the Reverse Stock Split, the Company shall deliver to each
of the Buyers (collectively, the “Reverse Stock Split Release Deliveries”) (i) a certificate executed by an officer of the Company and dated as of the date of delivery of such certificate, certifying as to the receipt of the Reverse
Stock Split Approval and the effectiveness of the Reverse Stock Split and (ii) a copy of the Certificate of Incorporation Amendment certified by the Secretary of State of the State of Delaware. 
  
 (iii) Immediately following the receipt by the Buyers of
Reverse Stock Release Deliveries, each of the Company and Langley Capital, L.P., as a representative of the Buyers, shall execute and deliver to the Escrow Agent, the Escrow Release Notice (as defined in the Escrow Agreement) which shall authorize
and direct the Escrow Agent to take the following actions (such actions, the “Release Actions”): 
  
 a. release and deliver to each Buyer the Notes registered in the name of such Buyer; 
  
 b. release and deliver to the Trustee the Notice of
Redemption, which the Escrow Agent shall date as of the date of the delivery of such Notice of Redemption; 
  
 c. release and deliver to the Trustee (or, if specified in the Escrow Release Notice, the paying agent designated by the Trustee) an
amount of money (which shall be specified in the Escrow Release Notice) sufficient to pay the Redemption 

  

 23 

 
Price (as defined in the Indenture) of, accrued interest on and all other payments due with respect to, the Existing Notes (such amount, the
“Redemption Amount”); and 
  
 d.
release and deliver to the Company an amount equal to (A) the amount of funds held by the Escrow Agent (including all interest that has accrued on such amounts) minus (B) the Redemption Amount. 
  
 (b) Bid Cure or Alternate Listing. The provisions set
forth in this Section 7(b) shall only apply if the Reverse Stock Split Approval is not received prior to April 30, 2004. 
  
 (i) If the Reverse Stock Split Approval is not received prior to April 30, 2004, the Company shall be required to use its reasonable best
efforts to either (A) cure the Company’s minimum bid deficiency requirement on the Principal Market as soon as reasonably practicable and in any event prior to June 4, 2004 (the “Bid Cure”) or (B) cause its Common Stock to be
listed or quoted on any of the Other Markets prior to June 4, 2004 (the “Alternate Listing”). 
  
 (ii) Promptly following the Company’s achievement of the Bid Cure or the Alternate Listing, the Company shall deliver to each of the
Buyers (collectively, the “Bid Cure/Alternate Listing Release Deliveries”) (A) in the case of a Bid Cure, (1) a certificate executed by an officer of the Company and dated as of the date of delivery of such certificate, certifying
as to the Company’s achievement of the Bid Cure and (2) all correspondence (if any) received by the Company from the Principal Market certifying as to the Company’s achievement of the Bid Cure or (B) in the case of an Alternate Listing,
(1) a certificate executed by an officer of the Company and dated as of the date of delivery of such certificate, certifying as to the Company’s Common Stock being listed or quoted on the Other Market and (2) a copy of the confirmation letter
received from the Other Market stating that the Common Stock is listed or quoted on the Other Market. 
  
 (iii) Immediately following the receipt by the Buyers of the Bid Cure/Alternate Listing Release Deliveries (provided that such deliveries
are received no later than June 4, 2004), each of the Company and Langley Capital, L.P., as a representative of the Buyers, shall execute and deliver to the Escrow Agent, the Escrow Release Notice which shall authorize and direct the Escrow Agent to
take the Release Actions. 
  
 (c) Optional
Closing. The provisions set forth in this Section 7(c) shall only apply if (1) the Reverse Stock Split Approval is not received prior to April 30, 2004 and (2) neither the Bid Cure nor the Alternate Listing is achieved prior to June 4, 2004.

  
 (i) If the Buyers have not received either
the Reverse Stock Split Release Deliveries before May 10, 2004 or the Bid Cure/Alternate Listing Release Deliveries before June 4, 2004, each Buyer shall have the option to either (A) effect the closing of the transactions contemplated by this
Agreement (the “Closing Election”) or (B) terminate this Agreement and the other Transaction Documents pursuant to Section 8(b) (the “Termination Election”). 
  
 (ii) No later than June 11, 2004, each Buyer shall be
required to provide the Company and Langley Capital, L.P., as a representative of the Buyers, with either (A) written notice of its exercise of the Closing Election (the “Closing Notice”) or (B) written notice of its exercise of the
Termination Election (the “Termination Notice”); provided, that if a Buyer fails 

  

 24 

 
to provide a Closing Notice by 5:00 p.m. (New York City time) on June 11, 2004, it shall be deemed that such Buyer has delivered the Termination Notice and
exercised the Termination Election. 
  
 (iii) No
later than June 14, 2004, the Company shall provide to the Buyers that have provided Closing Notices (the “Closing Buyers”) either (A) written notice that all of the Buyers have delivered Closing Notices or (B) written notice that
certain of the Buyers have delivered (or have been deemed to have delivered) Termination Notices (such Buyers the “Terminating Buyers”) which notice shall include the names of the Terminating Buyers and the principal amount of Notes
that the Terminating Buyers were to purchase under this Agreement. 
  
 (iv) No later than June 17, 2004, each Terminating Buyer shall have the right to provide the Company and Langley Capital, L.P., as a representative of the Buyers, with written notice (a “Revised Closing
Notice”) that such Buyer rescinds its Termination Notice and exercises the Closing Election; provided, that if a Terminating Buyer fails to provide a Revised Closing Notice by 5:00 p.m. (New York City time) on June 17, 2004, it shall
be deemed that such Terminating Buyer has not rescinded its Termination Notice and has continued to exercise the Termination Election. 
  
 (v) If all of the Buyers have properly delivered a Closing Notice or a Revised Closing Notice on or before June 17, 2004, then promptly
following receipt of Closing Notices and Revised Closing Notices from all of the Buyers (and in any event no later than June 18, 2004), each of the Company and Langley Capital, L.P., as a representative of the Buyers, shall execute and deliver to
the Escrow Agent, the Escrow Release Notice which shall authorize and direct the Escrow Agent to take the Release Actions. 
  
 (vi) If all of the Buyers have not properly delivered a Closing Notice or a Revised Closing Notice on or before June 17, 2004, then on
June 18, 2004 each of the Company and Langley Capital, L.P., as a representative of the Buyers, shall execute and deliver to the Escrow Agent, the Escrow Termination Notice which shall authorize and direct the Escrow Agent to take the following
actions: 
  
 a. release and deliver to each Buyer
the amount of funds deposited by such Buyer with the Escrow Agent (plus all interest that has accrued on such amount); and 
  
 b. release and deliver to the Company the Notice of Redemption and the Notes. 
  
 (vii) Notwithstanding anything in this Agreement or the
Transaction Documents to the contrary, each of the Buyers shall have the right to assign its rights and obligations under this Agreement to another Buyer; provided, that no Buyer shall be entitled to purchase an amount of Notes that, when
taken together with all other shares of Common Stock beneficially owned by such Buyer and its Affiliates, and after giving effect to the transactions contemplated by this Agreement, would result in such Buyer and its Affiliates beneficially owning
in excess of 9.99% of the number of shares of Common Stock outstanding immediately following the Closing (assuming the full conversion of the Notes at the Conversion Price). 
  

 25 

 (d) Buyer Representative. Each Buyer acknowledges and agrees that Langley Capital,
L.P. shall not be liable for any act done or omitted under this Section 7 or Section 4(h) as a representative of the Buyers while acting in good faith and in the exercise of reasonable judgment, and any act done or omitted pursuant to the advice of
counsel shall be conclusive evidence of such good faith. Each Buyer shall severally indemnify Langley Capital, L.P. and hold it harmless against any loss, liability or expense incurred without gross negligence or bad faith on the part of Langley
Capital, L.P. and arising out of or in connection with the acceptance or administration of its duties under this Section 7 and Section 4(h). 
  
 8. TERMINATION. 
  
 (a) Termination prior to the Subscription. In the event that the Subscription shall not have occurred with respect to a Buyer on or
before April 14, 2004, due to the Company’s failure to satisfy the conditions set forth in Section 6 above (and such Buyer’s failure to waive such unsatisfied condition(s)), such Buyer shall have the option to terminate this Agreement with
respect to itself at the close of business on such date without liability of any party to any other party and such Buyer shall cease to be deemed a Buyer under this Agreement. In the event that the Subscription shall not have occurred with respect
to the Company on or before April 14, 2004, due to a Buyer’s failure to satisfy the conditions set forth in Section 6 above (and the Company’s failure to waive such unsatisfied condition(s)), the Company shall have the option to terminate
this Agreement at the close of business on such date without liability of any party to any other party. Notwithstanding the foregoing, if this Agreement is terminated pursuant to this Section 8(a), the Company shall remain obligated to make the
payments to Morgan, Lewis & Bockius LLP described in Section 4(f) above. 
  
 (b) Termination prior to the Closing. If all of the Buyers have not properly delivered a Closing Notice or a Revised Closing Notice in accordance with Section 7(c) on or before June 17, 2004, than this
Agreement shall be terminated as of June 18, 2004. If this Agreement is terminated pursuant to this Section 8(b), this Agreement and the Transaction Documents (other than the Escrow Agreement) shall forthwith become null and void and there shall be
no liability on the part of any party hereto (and party shall be absolved from any and all liability) except that (i) each party shall remain obligated to perform the actions contemplated by Section 7(c)(vi), (ii) each party shall retain any and all
rights, claims or causes of action in existence at the time of such termination which are based upon, or arose incidental to, a breach of Section 7 and Section 4(e)(ii) by the other parties and such other parties shall remain liable for such
breaches, (iii) to the extent not previously paid, the Company shall remain obligated to make the payments to Morgan, Lewis & Bockius LLP described in Section 4(f) above and (iv) as soon as reasonably practicable following termination of this
Agreement (and in any event no later than June 23, 2004) the Company shall pay each Buyer the applicable Termination Fee (the date of the payment of the Termination Fee, the “Termination Fee Payment Date”). 
  
 (c) Termination Fee. For purposes of Section 8(b),
the “Termination Fee” shall mean an amount for each Buyer equal to (1) the product of (i) (A) the principal amount of Notes set forth opposite the applicable Buyer’s name on the Schedule of Buyers under the heading
“Principal Amount” multiplied by (B) 5.00% and (ii) a fraction, the numerator of which shall equal the number of calendar days that have elapsed between the Subscription Date and the Termination Fee Payment Date (including
the Subscription Date and the Termination Fee 

  

 26 

 
Payment Date) and the denominator of which shall equal 365 minus (2) the aggregate amount of interest that has accrued on the funds deposited by such
Buyer with the Escrow Agent and has been released to such Buyer pursuant to Section 7(c)(vi)(a). 
  
 9. MISCELLANEOUS. 
  
 (a) Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of
this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the
application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT
TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.  
  
 (b) Counterparts. This Agreement may be executed in two or more identical counterparts, all of which
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature shall be considered due execution and shall be binding
upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile signature. 
  
 (c) Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement. 
  
 (d)
Severability. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that
jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction. 
  
 (e) Entire Agreement; Amendments. This Agreement and the other Transaction Documents supersede all other prior oral or written
agreements between the Buyers, the Company, their Affiliates and Persons acting on their behalf with respect to the matters discussed herein, and this Agreement, the other Transaction Documents and the instruments 

  

 27 

 
referenced herein and therein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as
specifically set forth herein or therein, neither the Company nor any Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be amended other than by an instrument in
writing signed by the Company and the holders of the Notes representing at least a majority of the aggregate principal amount of the Notes, or, if prior to the Closing Date, the Company and the Buyers listed on the Schedule of Buyers as being
obligated to purchase at least a majority of the aggregate principal amount of the Notes. No provision hereof may be waived other than by an instrument in writing signed by the party against whom enforcement is sought. No such amendment shall be
effective to the extent that it applies to less than all of the holders of the Notes then outstanding. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction
Documents unless the same consideration also is offered to all of the parties to the Transaction Documents or holders of Notes, as the case may be. The Company has not, directly or indirectly, made any agreements with any Buyers relating to the
terms or conditions of the transactions contemplated by the Transaction Documents except as set forth in the Transaction Documents. Without limiting the foregoing, the Company confirms that, except as set forth in this Agreement, no Buyer has made
any commitment or promise or has any other obligation to provide any financing to the Company or otherwise. 
  
 (f) Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this
Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and
kept on file by the sending party); or (iii) one Business Day after deposit with an overnight courier service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall be:

  
 If to the Company: 
  
 Internet Capital Group, Inc. 
 690 Lee Road, Suite 310 
 Wayne, Pennsylvania
19087 
 Telephone:    (610) 727-6900 
 Facsimile:      (610) 727-6901 
 Attention:      
General Counsel and 
                        Vice President, Treasury and Tax 
  
 with a copy to: 
  
 Dechert LLP 
 1717 Arch Street 
 Philadelphia, Pennsylvania 19103 
 Telephone:    (215) 994-4000 
 Facsimile:      (215) 994-2222 
 Attention:       Henry N. Nassau, Esq. 
                        and Christopher G. Karras, Esq. 
  

 28 

 If to the Transfer Agent: 
  
 Mellon Investor Services LLC 
 PO Box 3315 
 South Hackensack, New Jersey 07606 
 Telephone:    (201) 329-8863 
 Facsimile:      (201) 329-8967 
 Attention:       Scott Bellinger

  
 If to a Buyer, to its address and facsimile number set forth
on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth on the Schedule of Buyers, 
  
 with a copy (for informational purposes only) to: 
  
 Morgan, Lewis & Bockius LLP 
 1701 Market
Street 
 Philadelphia, Pennsylvania 19103 
 Telephone:    (215) 963-5000 
 Facsimile:      (215)
963-5001 
 Attention:       Richard A. Silfen, Esq. 
                        and Robert G.
Robison, Esq. 
  
 or to such other address and/or facsimile number and/or to the
attention of such other Person as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice,
consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by
an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively. 
  
 (g) Successors and Assigns. This Agreement shall be
binding upon and inure to the benefit of the parties and their respective successors and assigns, including any purchasers of the Notes. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the holders of Notes representing at least a majority of the aggregate principal amount of the Notes then outstanding, including by merger or consolidation, except in accordance with the applicable provisions of the Notes with respect to
which the Company is in compliance with such provisions of the Notes. A Buyer may assign, without the consent of the Company, some or all of its rights hereunder to any Person to whom such Buyer assigns or transfers Securities, or the right to
acquire Securities, in accordance herewith, provided such transferee agrees in writing to be bound with respect to the transferred Securities to the provisions hereof that apply to the transferring Buyer, in which event such assignee shall be deemed
to be a Buyer hereunder with respect to such assigned rights. 
  

 29 

 (h) No Third Party Beneficiaries. This Agreement is intended for the benefit of
the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 
  
 (i) Survival. Unless this Agreement is terminated under Section 8, the representations and warranties
of the Company and the Buyers contained in Sections 2 and 3 and the agreements and covenants set forth in Sections 4, 5 and 9 shall survive the Subscription and the Closing. Each Buyer shall be responsible only for its own representations,
warranties, agreements and covenants hereunder. 
  
 (j) Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any
other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. 
  
 (k) Indemnification. 
  
 (i) In consideration of each Buyer’s execution and delivery of the Transaction Documents and acquiring
the Securities hereunder and thereunder and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless each Buyer and each other holder of the Securities
and all of their stockholders, partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives (including, without limitation, those retained in connection
with the transactions contemplated by this Agreement) (collectively, the “Buyer Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages (other than
consequential damages), and expenses in connection therewith (irrespective of whether any such Buyer Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements
(the “Buyer Indemnified Liabilities”), incurred by any Buyer Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction
Documents, (b) any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or (c) any cause of action, suit or claim brought or made against such Buyer Indemnitee by a third party (including for these
purposes a derivative action brought on behalf of the Company) and arising out of or resulting from (i) other than those arising from or resulting from a misrepresentation or breach of any representation or warranty made by such Buyer Indemnitee
contained in the Transaction Documents or a breach of any covenant, agreement or obligation by such Indemnitee contained in the Transaction Documents or from the gross negligence, willful misconduct or bad faith of such Buyer Indemnitee, the
execution, delivery, performance or enforcement of the Transaction Documents, (ii) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or (iii) other than those
arising from or resulting from a misrepresentation or breach of any representation or warranty made by such Indemnitee contained in the Transaction Documents or a breach of any covenant, agreement or obligation by such Buyer Indemnitee contained in
the Transaction Documents or from the gross negligence, 

  

 30 

 
willful misconduct or bad faith of such Buyer Indemnitee, the status of such Buyer or holder of the Securities as an investor in the Company. 
  
 (ii) In consideration of the Company’s execution and
delivery of the Transaction Documents and issuance of the Securities hereunder and thereunder and in addition to all of each Buyer’s other obligations under the Transaction Documents, each Buyer shall, severally and not jointly, defend,
protect, indemnify and hold harmless the Company and all of the Company’s officers, directors, agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this Agreement)
(collectively, the “Company Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages (other than consequential damages), and expenses in connection
therewith (irrespective of whether any such Company Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “Company Indemnified
Liabilities”), incurred by any Company Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by such Buyer in the Transaction Documents, (b) any breach of any
covenant, agreement or obligation of such Buyer contained in the Transaction Documents or (c) any cause of action, suit or claim brought or made against such Company Indemnitee by a third party and arising out of or resulting from, other than those
arising from or resulting from a misrepresentation or breach of any representation or warranty made by Company such Indemnitee contained in the Transaction Documents or a breach of any covenant, agreement or obligation by such Company Indemnitee
contained in the Transaction Documents or from the gross negligence, willful misconduct or bad faith of such Company Indemnitee, the execution, delivery, performance or enforcement of the Transaction Documents. 
  
 (iii) To the extent that the foregoing undertaking by the
Company and the Buyers may be unenforceable for any reason, the Company or such Buyer, as the case may be, shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under
applicable law. Except as otherwise set forth herein, the mechanics and procedures with respect to the rights and obligations under this Section 9(k) shall be the same as those set forth in Section 6 of the Registration Rights Agreement 

 
 (l) No Strict Construction. The language used in
this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 
  
 (m) Remedies. Each Buyer and each holder of the Securities shall have all rights and remedies set
forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under any law. Any Person having any rights under any
provision of any of the Transaction Documents shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of any of the Transaction Documents and to
exercise all other rights granted by law. Furthermore, the Company recognizes that in the event that it fails to perform, observe, or discharge any or all of its obligations under any of the Transaction Documents, any remedy at law may prove to be
inadequate relief to the Buyers. The Company therefore agrees that the Buyers shall be entitled to seek temporary and permanent injunctive relief in any such 

  

 31 

 
case without the necessity of proving actual damages and without posting a bond or other security. 
  
 (n) Payment Set Aside. To the extent that the Company
makes a payment or payments to the Buyers hereunder or pursuant to any of the other Transaction Documents or the Buyers enforce or exercise their rights hereunder or thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any
other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be
satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. 
  
 (o) Independent Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under any Transaction Document are
several and not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Buyers are in
any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Buyer confirms that it has independently participated in the negotiation of the transaction contemplated
hereby with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents,
and it shall not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose. 
  
 (p) Knowledge. For purposes of this Agreement, the terms “knowledge of the Company” or “the Company’s
knowledge” means the actual knowledge of the officers of the Company. 
  
 [Signature Pages Follow] 
  

 32 

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	COMPANY:
	 
	 INTERNET CAPITAL GROUP, INC.

		
	By:	 	 /s/ Suzanne L. Niemeyer

	 	 	

	 	 	 Name: Suzanne L. Niemeyer

	 	 	 Title: General Counsel.

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 BEAR STEARNS SECURITIES CORP.
 CUSTODIAN FOR JEFFREY THORP IRA
 ROLLOVER

		
	By:	 	 /s/ Jeffrey Thorp

	 	 	

	 	 	 Name: Jeffrey Thorp

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 COHANZICK ABSOLUTE RETURN
 MASTER FUND, LTD.

		
	By:	 	 /s/ David K. Sherman

	 	 	

	 	 	 Name: David K. Sherman

	 	 	 Title: Authorized Agent

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 COHANZICK CREDIT OPPORTUNITIES
 FUND, LTD.

		
	By:	 	 /s/ David K. Sherman

	 	 	

	 	 	 Name: David K. Sherman

	 	 	 Title: Authorized Agent

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 COHANZICK HIGH YIELD PARTNERS,
 L.P.

		
	By:	 	 /s/ David K. Sherman

	 	 	

	 	 	 Name: David K. Sherman

	 	 	 Title: Authorized Agent

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 GABRIEL CAPITAL, L.P.

		
	By:	 	 /s/ David K. Sherman

	 	 	

	 	 	 Name: David K. Sherman

	 	 	 Title: Authorized Agent

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 JMB CAPITAL PARTNERS, LP

		
	By:	 	 /s/ Ron D Silverton

	 	 	

	 	 	 Name: Ron D Silverton

	 	 	 Title: Authorized Signatory

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 JMG CAPITAL PARTNERS, LP

		
	By:	 	 /s/ Jonathan Glaser

	 	 	

	 	 	 Name: Jonathan Glaser

	 	 	 Title: Member Manager of the GP

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 JMG TRITON OFFSHORE FUND, LTD

		
	By:	 	 Jonathan Glaser

	 	 	

	 	 	 Name: Jonathan Glaser

	 	 	 Title: Member Manager of the Investment Manager

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 LANGLEY PARTNERS, L.P.

	 
	 by: Langley Capital, LLC, its General
 Partner

		
	By:	 	 /s/ Jeffrey Thorp

	 	 	

	 	 	 Name: Jeffrey Thorp

	 	 	 Title: Managing Member

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 MANCHESTER SECURITIES CORPORATION

		
	By:	 	 /s/ Paul Singer

	 	 	

	 	 	 Name: Paul Singer

	 	 	 Title: President

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 MASON CAPITAL, LP

	 MASON CAPITAL, LTD

	 GUGGENHEIM PORTFOLIO COMPANY X, LLC

	 
	By:	 	Mason Capital Management LLC, Investment Manager
		
	By:	 	 /s/ John C. Grizzetti

	 	 	

	 	 	 Name: John C. Grizzetti

	 	 	 Title: Chief Financial Officer

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 NORTHWOOD CAPITAL PARTNERS LP

	 
	 By: NwCapital Management LP, its General Partner

		
	By:	 	 /s/ Robert A. Berlacher

	 	 	

	 	 	 Name: Robert A. Berlacher

	 	 	 Title: Managing Member, NCP Advisors LLC

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	PORTSIDE GROWTH AND OPPORTUNITY FUND
	 
		
	By:	 	 /s/ Jeffrey Smith

	 	 	

	 	 	 Name: Jeffrey Smith

	 	 	 Title: Authorized Signatory

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 SCOGGIN CAPITAL MANAGEMENT, LP II

	 
	 By: S&E Partners, LP, its general partner

	 
	 By: Scoggin, Inc., its general partner

	 
		
	By:	 	 /s/ Craig Effron

	 	 	

	 	 	 Name: Craig Effron

	 	 	 Title: President

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 SCOGGIN INTERNATIONAL FUND, LTD.

	 
	 By: Scoggin, LLC, its trading advisor

	 
		
	By:	 	 /s/ Craig Effron

	 	 	

	 	 	 Name: Craig Effron

	 	 	 Title: Managing Member

  

 IN WITNESS WHEREOF, each Buyer and the Company has caused their respective signature page to this
Securities Purchase Agreement to be duly executed as of the date first written above. 
  

			
	BUYER:
	 
	 TOPAZ PARTNERS LP

	 
		
	By:	 	 /s/ Kevin Schweitzer

	 	 	

	 	 	 Name: Kevin Schweitzer

	 	 	 Title: Portfolio Manager

  

 Schedule I 
  

Schedule of Buyers 
  

											
	 Buyer

	  	 Address and
 Facsimile Number

	  	 Representative

	  	 Principal
 Amount

	  	 Purchase
 Price

	 Bear Stearns
 Securities Corp.
 Custodian for
 Jeffrey Thorp IRA
 Rollover
	  	 535 Madison Avenue
 7th Floor
 New York, NY 10022
 Fax: 212-850-7589
 Attn: Jeffrey Thorp
	  	 Morgan, Lewis & Bockius LLP
 1701 Market
Street
 Philadelphia, PA 19103
 Fax: 215-963-5001
 Attn: Richard A. Silfen, Esq. and Robert G. Robison, Esq.
	  	$	7,000,000	  	$	7,000,000
					
	 Cohanzick Credit
 Opportunities
 Fund, Ltd.
	  	 427 Bedford Road
 Suite 260
 Pleasantville, NY 10570
 Fax: 914-992-9817
 Attn: David K. Sherman
	  	 Nixon Peabody LLP
 100 Summer Street
 Boston, MA 02110
 Fax: 866-382-6139
 Attn: Richard Stein
	  	$	3,400,000	  	$	3,400,000
					
	 Cohanzick High
 Yield Partners, L.P.
	  	 427 Bedford Road
 Suite 260
 Pleasantville, NY 10570
 Fax: 914-992-9817
 Attn: David K. Sherman
	  	 Nixon Peabody LLP
 100 Summer Street
 Boston, MA 02110
 Fax: 866-382-6139
 Attn: Richard Stein
	  	$	2,500,000	  	$	2,500,000
					
	 Cohanzick
 Absolute Return
 Master Fund, Ltd.
	  	 427 Bedford Road
 Suite 260
 Pleasantville, NY 10570
 Fax: 914-992-9817
 Attn: David K. Sherman
	  	 Nixon Peabody LLP
 100 Summer Street
 Boston, MA 02110
 Fax: 866-382-6139
 Attn: Richard Stein
	  	$	201,000	  	$	201,000
					
	 Gabriel Capital,
 L.P.
	  	 450 Park Avenue
 32nd Floor
 New York, NY 10022
 Fax: 914-992-9817
 Attn: David K. Sherman
  
 with copy to:
 450 Park Avenue
 Suite 3201
 New
York, NY 10022
 Fax: 212-759-0368
 Attn: Mark
Weiner
	  	 Nixon Peabody LLP
 100 Summer Street
 Boston, MA 02110
 Fax: 866-382-6139
 Attn: Richard Stein
	  	$	3,900,000	  	$	3,900,000
					
	 Guggenheim
 Portfolio Company
 X, LLC
	  	 110 East 59th
Street
 30th
Floor
 New York, NY 10022
 Fax: 212-644-4264
 Attn: John C. Grizzetti
	  	 Thelen Reid & Priest
 875 Third Avenue
 New York, NY 10022
 212-603-6783
 Fax: 212-603-2001
 Attn: Richard Swanson
	  	$	1,309,000	  	$	1,309,000
					
	 JMB Capital
 Partners, LP
	  	 1999 Avenue of the Stars
 Suite 2040
 Los Angeles, CA 90067
 Fax: 310-286-6662
 Attn: Ron D. Silverton
	  	 Latham & Watkins LLP
 633 West Fifth
Street
 Suite 4000
 Los Angeles, CA 90071
 Fax: 213-891-8763
 Attn: Michael A. Treska
	  	$	5,000,000	  	$	5,000,000
					
	 JMG Capital
 Partners, LP
	  	 1999 Avenue of the Stars
 Suite 2530
 Los Angeles, CA 90067
 Fax: 310-201-2759
 Attn: Noelle Newton
	  	None.	  	$	2,500,000	  	$	2,500,000

  

											
	 JMG Triton
 Offshore Fund, Ltd
	  	 1999 Avenue of the Stars
 Suite 2530
 Los Angeles, CA 90067
 Fax: 310-201-2759
 Attn: Noelle Newton
	  	None.	  	$	2,500,000	  	$	2,500,000
					
	 Langley Partners,
 LP
	  	 535 Madison Avenue
 7th Floor
 New York, NY 10022
 Fax: 212-850-7589
 Attn: Jeffrey Thorp
	  	 Morgan, Lewis & Bockius LLP
 1701 Market
Street
 Philadelphia, PA 19103
 Fax: 215-963-5001
 Attn: Richard A. Silfen, Esq. and Robert G. Robison, Esq.
	  	$	3,000,000	  	$	3,000,000
					
	 Manchester
 Securities
 Corporation
	  	 c/o Elliott Management Corporation
 712 5th
Ave
 35th floor
 New York, NY 10019
 Fax: 212-974-2092
 Attn: Elliot Greenberg (back office), Brett Cohen and Nadav
Manham
	  	 Kleinberg, Kaplan, Wolff, & Cohen, P.C.
 551 Fifth
Avenue
 New York, NY 10176
 Fax: 212-986-8866
 Attn: Larry Hui
	  	$	3,500,000	  	$	3,500,000
					
	Mason Capital, LP	  	 110 East 59th
Street
 30th
Floor
 New York, NY 10022
 Fax: 212-644-4264
 Attn: John C. Grizzetti
	  	 Thelen Reid & Priest
 875 Third Avenue
 New York, NY 10022
 212-603-6783
 Fax: 212-603-2001
 Attn: Richard Swanson
	  	$	5,070,000	  	$	5,070,000
					
	Mason Capital, Ltd	  	 110 East 59th
Street
 30th
Floor
 New York, NY 10022
 Fax: 212-644-4264
 Attn: John C. Grizzetti
	  	 Thelen Reid & Priest
 875 Third Avenue
 New York, NY 10022
 212-603-6783
 Fax: 212-603-2001
 Attn: Richard Swanson
	  	$	8,620,000	  	$	8,620,000
					
	 Northwood Capital
 Partners LP
	  	 1150 First Avenue
 Suite 600
 King of Prussia, PA 19406
 Fax: 610-783-4788
 Attn: Robert Berlacher
	  	None.	  	$	1,000,000	  	$	1,000,000
					
	 Portside Growth
 and Opportunity
 Fund
	  	 c/o Ramius Capital Group, LLC
 666 Third
Avenue,
 26th Floor
 New York, NY 10017
 Fax: 212-845-7999
 Attn: Jeff Smith and
 Roger Anscher
	  	None.	  	$	3,500,000	  	$	3,500,000
					
	 Scoggin Capital
 Management, LP II
	  	 660 Madison Avenue
 20th Floor
 NY, NY 10021
 Fax: 212-355-7480
 Attn: Craig Efron
	  	None.	  	$	1,000,000	  	$	1,000,000

  

											
					
	 Scoggin
 International Fund,
 Ltd.
	  	 660 Madison Avenue
 20th Floor
 NY, NY 10021
 Fax: 212-355-7480
 Attn: Craig Efron
	  	None.	  	$	1,000,000	  	$	1,000,000
					
	Topaz Partners LP	  	 c/o Jemmco Capital Corp
 900 Third Avenue
 11th Floor
 New York, N.Y. 10022
 Fax: 212-644-1175
 Attn: Kevin Schweitzer
	  	 Akin Gump
 900 Third Avenue
 11th Floor
 NY, NY 10022
 Fax: 212-872-1002
 Attn: Lorne Smith
	  	$	5,000,000	  	$	5,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]